PRAME is a target expressed in more than 50 cancers, including melanoma, lung, ovarian, breast, and endometrial cancer, among many others. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. To do so safely and effectively requires deep expertise in immunology, drug development and beyond.
Immatics has the broadest PRAME franchise with the most indications and therapeutic modalities.
Clinical trials
Immatics is evaluating its targeted PRAME cell therapies and bispecific product candidates and actively enrolling patients in ongoing clinical trials.
Press releases
Follow our progress as we advance PRAME therapies from lab to clinic and beyond.
This week, Immatics scientists gathered in Tübingen, Germany, for Science Day,...
ICYMI: The Immatics team had an eventful weekend full of meetings and presentations at the 2025 ASCO
February 11th marks the International Day of Women and Girls in Science—a day dedicated to celebrating